APW
DSGN icon

Allied Private Wealth’s Design Therapeutics DSGN Stock Holding History

Allied Private Wealth’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Buy
+880
New +$11K 0.01% 472

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Allied Private Wealth's DSGN Position: Q2 2026 in Review

Allied Private Wealth opened a new position in Design Therapeutics (DSGN) in Q2 2026: 880 shares worth $13.4K. The stake represents 0.01% of the portfolio and ranks #472 among its holdings.

137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Allied Private Wealth held 880 shares of Design Therapeutics worth $13.4K as of Q2 2026.
  • Design Therapeutics was a new Allied Private Wealth position in Q2 2026.
  • Design Therapeutics made up 0.01% of Allied Private Wealth's portfolio in Q2 2026, its #472 holding.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Allied Private Wealth's 13F filing for Q2 2026, filed 9 Jul 2026.